PTC Therapeutics

PTC Therapeutics to Participate at Upcoming Investor Conferences

Retrieved on: 
星期四, 五月 2, 2024
PTC Therapeutics, Therapy, PTC

WARREN, N.J., May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:

Key Points: 
  • WARREN, N.J., May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
    The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
  • It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

Parent Project Muscular Dystrophy Celebrates 30th Anniversary with Launch of PPMD Together Meeting Series in Cincinnati, Ohio

Retrieved on: 
星期三, 四月 17, 2024
City, Hope, PTC Therapeutics, Today, Series, Empowerment, Becker muscular dystrophy, Parent, Research, Human, Catalyst Pharmaceuticals, Policy, Family, PPMD, Sarepta Therapeutics, Diagnosis, Duchenne muscular dystrophy, Grandparent, Therapy

CINCINNATI, April 17, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), proudly marks its 30th anniversary at the launch of the PPMD Together meeting series, taking place April 19-20, 2024, in Cincinnati, Ohio. Founded three decades ago by a small group of passionate parents and grandparents within the Duchenne community, PPMD has grown into a beacon of hope, driven by the unwavering dedication of parents, families, and individuals living with Duchenne and Becker.

Key Points: 
  • CINCINNATI, April 17, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , proudly marks its 30th anniversary at the launch of the PPMD Together meeting series, taking place April 19-20, 2024, in Cincinnati, Ohio.
  • In April 1994, Cincinnati served as the birthplace of PPMD, where a handful of determined families joined forces to confront the challenges posed by Duchenne.
  • PPMD selected the location and date of the first PPMD Together meeting to celebrate the 30th anniversary of the organization in its hometown of Cincinnati, April 19-20, 2024.
  • Sponsorship for the PPMD Together meeting has been provided by Catalyst Pharmaceuticals, Edgewise Therapeutics, NS Pharma, Pfizer, PTC Therapeutics, and Sarepta Therapeutics in accordance with PPMD's Corporate Relations Policy .

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

Retrieved on: 
星期四, 四月 11, 2024
Therapy, PTC Therapeutics, PTC

SOUTH PLAINFIELD, N.J., April 11, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m.

Key Points: 
  • SOUTH PLAINFIELD, N.J., April 11, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m.
  • To access the call by phone, please click here to register and you will be provided with dial-in details.
  • To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
  • The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

Retrieved on: 
星期二, 三月 19, 2024
Ornithine, Brain, PTC Therapeutics, Partnership, Deficiency, Patient, Death, Life, Therapy, Spine, PTC, FDA, AADC, BLA, Food, Pharmaceutical industry

If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.

Key Points: 
  • If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.
  • “AADC Deficiency is a devastating rare pediatric movement disorder that causes significant developmental delays and autonomic symptoms starting from birth.
  • Patients with AADC deficiency are at a high risk of death in the first decade of life,” stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro.
  • Through our partnership with PTC, we are demonstrating our commitment to drive progress for the AADC Deficiency community.”

Global Cell and Gene Therapy Markets Report 2024-2028: Focus on Zolgensma, Yescarta, Kymriah, Abecma, Maci, Tecartus, Epicel - ResearchAndMarkets.com

Retrieved on: 
星期三, 四月 3, 2024
Health, Genetics, Growth, PTC Therapeutics, Prevalence, Gene editing, ESG, CSL Behring, Roche, Etranacogene dezaparvovec, Gene, Gilead Sciences, Cancer, Eladocagene exuparvovec, Therapy, CRISPR, Mallinckrodt, PTC, Probability, BLA, Pharmaceutical industry

The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cell and Gene Therapy Market is expected to grow at a compound annual growth rate (CAGR) of 26.40% from 2023 through 2028.
  • The scope of this study encompasses an investigation of the cell and gene therapy market.
  • The report analyzes cell and gene therapy market based on therapy type, product, application, and region.

PTC Therapeutics Provides Key Regulatory Updates

Retrieved on: 
星期二, 三月 19, 2024
PTC Therapeutics, MAA, Ataluren, Patient, PKU, NDA, EMA, Eladocagene exuparvovec, Duchenne muscular dystrophy, Therapy, PTC, FDA, AADC, BLA, Pharmaceutical industry

SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. In addition, based on recent feedback from the FDA, PTC plans to re-submit an NDA for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC expects to make the NDA resubmission by mid-year.

Key Points: 
  • SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.
  • In addition, based on recent feedback from the FDA, PTC plans to re-submit an NDA for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
  • PTC expects to make the NDA resubmission by mid-year.
  • The data collected to date continue to demonstrate the transformative clinical benefits the gene therapy provides to patients," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics.

Atomic AI Announces Appointments of New Independent Member to its Board of Directors and Additions to the Scientific Advisory Board

Retrieved on: 
星期四, 二月 22, 2024
Research, Other Health, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Other Science, Molecule, Organic chemistry, Viral, Senior, Janssen Pharmaceuticals, Dartmouth College, SAB, Neuroscience, Beclabuvir, PTC Therapeutics, University, RNA, Jan Vansina, RSV, HIV-1, Atomic, Johnson & Johnson, Stroke, Bristol Myers Squibb, MBA, BMS, Therapy, Journal, HCV, PTC, Drug discovery, Meanwell, McArdle Laboratory, American Academy, Royal Society, Daclatasvir, Harvard University, Asunaprevir, Doctor of Philosophy, Thrombosis, Rutgers University, Patient, Outline of physical science, American Chemical Society, Deep learning, Publication, Cancer, Medicinal chemistry, Pharmaceutical industry

Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).

Key Points: 
  • Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).
  • “We are extremely pleased to have these highly regarded, experienced biotech leaders join in our efforts and believe in our mission,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI.
  • Peltz’s experience will help shape our strategy as we endeavor to streamline the discovery and development of novel therapies.
  • “They have demonstrated tremendous progress integrating deep learning foundation models with experimental results to be able to predict and optimize RNA structures to enable rational drug design.

PTC Therapeutics to Participate at Upcoming Investor Conferences

Retrieved on: 
星期二, 二月 27, 2024
PTC Therapeutics, PTC, Therapy

SOUTH PLAINFIELD, N.J., Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:

Key Points: 
  • SOUTH PLAINFIELD, N.J., Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
    The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
  • It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期四, 二月 15, 2024
PTC Therapeutics, EST, PTC, Therapy

SOUTH PLAINFIELD, N.J., Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.
  • To access the call by phone, please click here to register and you will be provided with dial-in details.
  • To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
  • The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .

Royalty Pharma Reports Q4 and Full Year 2023 Results

Retrieved on: 
星期四, 二月 15, 2024
MorphoSys, Pfizer, European Commission, Recurrence, Docetaxel, Roche, Cystic fibrosis, Share repurchase, FDA, Food, Schizophrenia, Growth, Sacituzumab govitecan, PTC, Vertex, Astellas Pharma, Risdiplam, Metastasis, Projection, KarXT, Bristol Myers Squibb, PTC Therapeutics, Endocrine gland, Lung cancer, Civil service commission, JAK, Therapy, Tourette syndrome, Webcast, Patient, Cytokinetics, Eastern Time Zone, Novartis, Ruxolitinib, NDA, Pharmaceutical industry

In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.

Key Points: 
  • In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.
  • Royalty Pharma began repurchasing its Class A ordinary shares in April 2023 under a $1.0 billion multi-year share repurchase program.
  • During the fourth quarter of 2023, Royalty Pharma announced new transactions of up to $1.6 billion.
  • Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2023 results today at 8:00 a.m., Eastern Time.